Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 211

Sort by

Sort Order Select

Journal Articles

Factor-Associated Risk Factors of Mild Cognitive Impairment in Thalassemia Patients : Probable Role of FGF21

Wasan Theerajangkhaphichai, MD, Adisak Tantiworawit, MD, Jirapas Sripetchwandee, PhD, Nattayaporn Apaijai, PhD, Sirawit Sriwichaiin, MD, Napatsorn Saiyasit, Kewarin Jinawong, Busarin Arunsak, Pokpong Piriyakhuntorn, MD, Thanawat Rattanathammethee, MD, Sasinee Hantrakool, MD, Chatree Chai-Adisaksopha, MD PhD, Ekarat Rattarittamrong, MD, Lalita Norasetthada, MD, Pimlak Charoenkwan, MD, Nipon Chattipakorn, MD PhD, Siriporn Chattipakorn, DDS, PhD

Blood (2019) 134 (Supplement_1): 2251.

https://doi.org/10.1182/blood-2019-125182

Published: 2019

Journal Articles

Assessing Feasibility of a Focused Geriatric Assessment in Older Adults with Sickle Cell Disease to Address Functional Risk Factors for Morbidity and Mortality

Charity I Oyedeji, MD, Carl Pieper, PhD, Katherine Hall, PhD, Miriam Morey, PhD, Heather Whitson, MD MHS, John J. Strouse, MD, PhD

Blood (2019) 134 (Supplement_1): 518.

https://doi.org/10.1182/blood-2019-122634

Published: 2019

Journal Articles

Impact of Combining Frailty Assessment Systems to Select Elderly Myeloma Patients Eligible for Autologous Peripheral Blood Stem Cell Transplantation

Akira Tanimura, Koji Okazaki, MD, Yuko Okuda, MD, Risen Hirai, MD, Daisuke Kudo, MD, Masataka Takeshita, MD PhD, Akiyoshi Miwa, MD, PhD

Blood (2019) 134 (Supplement_1): 5706.

https://doi.org/10.1182/blood-2019-122084

Published: 2019

Journal Articles

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma

Jarrod Longcor, Kate Oliver, BS

Blood (2019) 134 (Supplement_1): 1864.

https://doi.org/10.1182/blood-2019-131806

Published: 2019

Journal Articles

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Blood (2019) 134 (Supplement_1): 3034.

https://doi.org/10.1182/blood-2019-128850

Published: 2019

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

Journal Articles

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

Rajneesh Nath, MD, Eileen M Geoghegan, Matthew L. Ulrickson, MD, Jennifer A Spross, MA, Renee H Lichtenstein, BA, Sandy Konerth, MS, Darrell R. Fisher, PhD, Qing Liang, PhD, Dale Ludwig, PhD BS, Vijay Reddy, MD PhD, Mark S. Berger, MD, Boglarka Gyurkocza, MD

Blood (2019) 134 (Supplement_1): 1958.

https://doi.org/10.1182/blood-2019-128838

Published: 2019

Journal Articles

The Revised Myeloma Comorbidity Index (R-MCI) As a Promising Approach for Predicting Overall (OS)- and Progression-Free (PFS) Survival and Optimizing Therapy Strategies in Multiple Myeloma (MM) Patients (pts) - Comparative Analysis of 5 Comorbidity Indices (CI), Including Retro- and Prospective Applicability

Katja Schoeller, Gabriele Ihorst, Sophia Scheubeck, Max Holler, Sandra M. Woerner, Heike Reinhardt, Stefan P. Müller, Justus Duyster, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2019) 134 (Supplement_1): 3474.

https://doi.org/10.1182/blood-2019-127030

Published: 2019

Journal Articles

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Blood (2019) 134 (Supplement_1): 4394.

https://doi.org/10.1182/blood-2019-126080

Published: 2019

Journal Articles

Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL)

Blood (2019) 134 (Supplement_1): 322.

https://doi.org/10.1182/blood-2019-124590

Published: 2019

Journal Articles

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Patrick J. Stiff, MD, Emad Ibrahim, MBBCh, MD, Anusha Vallurupalli, MBBS, Elizabeth H. Cull, MD, Damian J. Green, MD, Kate Oliver, BS, Jarrod Longcor

Blood (2019) 134 (Supplement_1): 144.

https://doi.org/10.1182/blood-2019-131014

Published: 2019

Journal Articles

Impact of Neurocognitive Dysfunction in a Veteran Population Undergoing First Outpatient Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Shakira J. Grant, MBBS, Lindsay M. Hannan, MD MSPH, Jessica L. Brand, PhD, Robert E. Richard, MD PhD, Daniel Y. Wu, MD, Solomon A. Graf, MD, Jonathan Grim, MD PhD, Nicholas Burwick, MD, Thomas R. Chauncey, MD PhD

Blood (2019) 134 (Supplement_1): 5883.

https://doi.org/10.1182/blood-2019-122580

Published: 2019

Journal Articles

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Bae P Chu, MPH, Neeta Pandit-Taskar, MD, Boglarka Gyurkocza, MD, Qing Liang, PhD, Daniel Miodownik, MPH, Vijay Reddy, MD PhD, Mark S. Berger, MD, Lawrence T. Dauer, PhD

Blood (2019) 134 (Supplement_1): 5839.

https://doi.org/10.1182/blood-2019-131230

Published: 2019

Journal Articles

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Phuong T. Vo, MD, Ted Gooley, PhD, Joseph G. Rajendran, MD, Darrell R. Fisher, PhD, Johnnie J. Orozco, MD PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Robyn Haaf, BS, Margaret E. Nartea, BS, Rainer F. Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD PhD, John M. Pagel, MD PhD, Brenda M. Sandmaier, MD

Blood (2018) 132 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2018-99-111915

Published: 2018

Journal Articles

Targeted Conditioning of Iomab-B ( 131 I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

Edward Agura, MD, Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Mark R. Litzow, MD, Benjamin K. Tomlinson, MD, Sunil Abhyankar, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Hannah K. Choe, MD, Partow Kebriaei, MD, James M. Foran, MD, George Chen, MD, Moshe Yair Levy, MD, Hillard M Lazarus, MD, Sergio Giralt, MD, Mark S. Berger, MD, Vijay Reddy, MD PhD, John M. Pagel, MD PhD

Blood (2018) 132 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2018-99-111914

Published: 2018

Journal Articles

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Jasmine Zain, MD, Jennifer Simpson, Joycelynne Palmer, Jeffrey Wong, MD, Savita Dandapani, MD PhD, David Colcher, PhD, Nicole Karras, MD, Alex F. Herrera, MD, Amandeep Salhotra, MD, Auayporn P. Nademanee, MDBS, Ryotaro Nakamura, MD, Eileen P. Smith, MD, Ni-Chun Tsai, David Yamauchi, MD, Kofi Poku, PharmD, Van Biglang-awa, PharmD, John E. Shively

Blood (2018) 132 (Supplement 1): 611.

https://doi.org/10.1182/blood-2018-99-116907

Published: 2018

Journal Articles

Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience

Blood (2018) 132 (Supplement 1): 4651.

https://doi.org/10.1182/blood-2018-99-117767

Published: 2018

Journal Articles

Autologous Stem Cell Transplantation in Newly Diagnosed Elderly Multiple Myeloma Patients: A Single Centre Experience

Tamara Berno, MD, Marcello Riva, MD, Lucia Ammirati, MD, Luca Brugnaro, Dr, Carmela Gurrieri, MD, Antonio Branca, MD, Nabergoj Mitja, MD, Andrea Visentin, MD, Silvia Imbergamo, MD, Francesco Piazza, MD, Livio Trentin, MD, Renato Zambello, MD, Gianpietro Semenzato, MD

Blood (2017) 130 (Supplement 1): 5532.

https://doi.org/10.1182/blood.V130.Suppl_1.5532.5532

Published: 2017

Journal Articles

Functional Assessment (FA) in Multiple Myeloma (MM) Patients Predicts Survival: Use of Most Valuable Comorbidity Scores and Functional Tests in a German Study Group (Deutsche Studiengruppe Multiples Myelom [DSMM]) Incentive

Sophia Scheubeck, Gabriele Ihorst, Sandra M. Dold, MSc, Katja Schoeller, Martin Boeker, PD, Stefan J. Müller, PharmD, Johannes M. Waldschmidt, MD, Rebeka Javorniczky, MD, Alessandra Larocca, Margrit Ott, MD, Hermann Einsele, Justus Duyster, Ralph Wäsch, MD, Monika Engelhardt

Blood (2017) 130 (Supplement 1): 3436.

https://doi.org/10.1182/blood.V130.Suppl_1.3436.3436

Published: 2017

Journal Articles

Cognitive Function in Older Adults with Hematological Malignancies

Thuy Thi Koll, MD, Noel S. Bruner, Vijaya R. Bhatt, MBBS, Tanya M. Wildes, MDMSCI, Apar K Ganti, MD, Diane K. Hendricks, LCSW, Dennis P. McNeilly, Psy.D

Blood (2017) 130 (Supplement 1): 3440.

https://doi.org/10.1182/blood.V130.Suppl_1.3440.3440

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Factor-Associated Risk Factors of Mild Cognitive Impairment in Thalassemia Patients : Probable Role of FGF21

Assessing Feasibility of a Focused Geriatric Assessment in Older Adults with Sickle Cell Disease to Address Functional Risk Factors for Morbidity and Mortality

Impact of Combining Frailty Assessment Systems to Select Elderly Myeloma Patients Eligible for Autologous Peripheral Blood Stem Cell Transplantation

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 (CLR 131) in Patients with Relapsed or Refractory Multiple Myeloma

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL)

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Impact of Neurocognitive Dysfunction in a Veteran Population Undergoing First Outpatient Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Targeted Conditioning of Iomab-B ( 131 I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen"

Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17- Year Experience

Autologous Stem Cell Transplantation in Newly Diagnosed Elderly Multiple Myeloma Patients: A Single Centre Experience

Functional Assessment (FA) in Multiple Myeloma (MM) Patients Predicts Survival: Use of Most Valuable Comorbidity Scores and Functional Tests in a German Study Group (Deutsche Studiengruppe Multiples Myelom [DSMM]) Incentive

Cognitive Function in Older Adults with Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only